Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Gastro-enteropancreatic neuroendocrine tumor × Irinotecan × 90 days × Clear all

Sponsor

Conditions

Colorectal Neoplasms 25 Pancreatic Neoplasms 15 Neuroblastoma 9 Neoplasm Metastasis 9 Colonic Neoplasms 7 Stomach Neoplasms 6 Sarcoma, Ewing 6 Rhabdomyosarcoma 5 Rectal Neoplasms 5 Neoplasms 5 Medulloblastoma 4 Esophageal Squamous Cell Carcinoma 4 Sarcoma 3 Recurrence 3 Ovarian Neoplasms 3 Osteosarcoma 3 Esophageal Neoplasms 3 Ependymoma 3 Endometrial Neoplasms 3 Cholangiocarcinoma 3 Adenocarcinoma Of Esophagus 3 Wilms Tumor 2 Uterine Cervical Neoplasms 2 Small Cell Lung Carcinoma 2 Pathologic Complete Response 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Fibrolamellar hepatocellular carcinoma 2 Colorectal Adenocarcinoma 2 Breast Neoplasms 2 Biliary Tract Neoplasms 2

Interventions

lutetium Lu 177 dotatate 3 pasireotide 2 Octreotide 2 lanreotide 1 copper dotatate CU-64 1 abemaciclib 1 Sunitinib 1 Receptor-Like Protein Tyrosine Phosphatases, Class 2 1 Lutetium-177 1 Lutetium 1 Everolimus 1 E-7386 1 Cryotherapy 1 Acupuncture Therapy 1 Acupressure 1 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡